Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million,
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights to a biologic for the treatment of cold agglutinin disease, with milestone payments of up to $250 million.
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.
Recordati buys rare disease drug Enjaymo in $825M Sanofi deal
Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi SA,
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo.
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic
Recordati acquires rights to Enjaymo
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines.
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln
Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.
20h
on MSN
Sanofi inks $1B deal to sell autoimmune disorder therapy
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
3d
Buy Rating Affirmed for Annexon Biosciences Amidst Promising Clinical Developments and Market Potential
Analyst Derek Archila of Wells Fargo maintained a Buy rating on Annexon Biosciences (ANNX – Research Report), retaining the price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
US adds 254,000 jobs
Yellow jackets swarm in NC
Registration deadlines
US launches airstrikes
Judge denies request
Bills Hall of Famer dies
Antarctica turning green
Mich. double voting incident
WH briefing appearance
Plastic-eating bacteria
IV fluid supplies dwindle
Won’t renew CHNV parole
To stop linking to NZ news?
Read seeks to delay lawsuit
CA dairy workers infected
NHTSA opens probe
Bird flu vaccine supply boost
Union skips endorsement
Stellantis sues UAW
ULA launches Vulcan rocket
SCOTUS allows EPA rules
To add Hyundai EVs
To lead LA police force
Debt plan blocked again
To weigh TX death row case
Water fluoridation research
Free tax filing expansion
Tropical Storm Leslie forms
Related topics
Sanofi
Recordati
Enjaymo
Feedback